Insights+: The US FDA New Drug Approvals in July 2020

The US FDA has approved multiple NDAs and BLAs in July 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 59 novel products so far in 2020, including 8 in July 2020. Additionally,…

BySenior EditorAugust 27, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in June 2020

The US FDA has approved multiple NDAs and BLAs in Jun 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 51 novel products so far in 2020, including 8 in Jun 2020. Additionally,…

BySenior EditorJuly 24, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in March and April 2020

The US FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 48 new products so far in 2019.However, there is a significant increase in multiple diseases while the new approvals are helping and advancing the changes to understand, diagnose, and treat the diseasesOur team…

BySenior EditorMay 15, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of March 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyHence, the providers are more likely to adopt biosimilars as a 'reference product to biologics' possessing similar therapeutic propertiesThe US FDA took an initiative to develop new pathways for Insulin biosimilars. Our team at PharmaShots has…

BySenior EditorApril 10, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of February 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patientsThe Korean firm, Celltrion's Remsima also showed some updates in fields of approval and…

BySenior EditorMarch 6, 2020

INSIGHTS+

Insights+: COVID-19 Healthcare News Monthly Updates – February 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named 'SARS-CoV-2'(severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named 'Coronavirus Disease 2019'(COVID-19). The outbreak of the respiratory disease was first detected in Wuhan…

BySenior EditorFebruary 28, 2020

INSIGHTS+

Insights+: COVID-19 Healthcare News Monthly Updates – March 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it.The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019.PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where…

BySenior EditorJanuary 31, 2020

INSIGHTS+

Insights+: COVID-19 Healthcare News Monthly Updates – April 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop itThe outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where…

BySenior EditorJanuary 5, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in November 2019

The US FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 35 new products so far in 2019. In 2018 FDA approved 59 novel products including 42 New Chemical Entities and 17 Biologics while breaking its last year's record of approvals. However, there is a significant…

BySenior EditorDecember 13, 2019

INSIGHTS+

Insights+ Key Biosimilars Events of May 2019

Biosimilars are going in market with vast emerging needs of people for multiple diseases. The biologics that are too costly to be used in the markets. Hence physicians are developing biosimilars a reference product to biologics which are biologically similar to biologics. Our team at PharmaShots have summarized some of the news regarding biosimilars in…

BySenior EditorJune 4, 2019

Insights+: The US FDA New Drug Approvals in July 2020

Insights+: The US FDA New Drug Approvals in June 2020

Insights+: The US FDA New Drug Approvals in March and April 2020

Insights+ Key Biosimilars Events of March 2020

Insights+ Key Biosimilars Events of February 2020

Insights+: COVID-19 Healthcare News Monthly Updates – February 2020

Insights+: COVID-19 Healthcare News Monthly Updates – March 2020

Insights+: COVID-19 Healthcare News Monthly Updates – April 2020

Insights+: The US FDA New Drug Approvals in November 2019

Insights+ Key Biosimilars Events of May 2019

Contact US

OUR INFORMATION

FOLLW US

FOLLW US

Sign Up to Our Newsletter